TAK Form 144: 28.5k ADS Insider Sale Planned for July 2025
Rhea-AI Filing Summary
The Form 144 filing indicates that an unidentified holder intends to sell 28,552 American Depositary Shares (ADSs) of Takeda Pharmaceutical Company Ltd. (NYSE: TAK) through Interactive Brokers on or about 9 July 2025. The planned sale represents an aggregate market value of US$440,271.84, implying an approximate price of US$15.42 per ADS. The shares derive from restricted stock unit (RSU) awards that vested on 1 July 2025. No other securities have been sold by the filer in the past three months, and the total shares outstanding for Takeda are disclosed as 123,490,548 ADSs, making the proposed sale equal to roughly 0.02 % of the class. No adverse information about Takeda’s operations is asserted, and the filer affirms compliance with Rule 144 and Rule 10b5-1 representations.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small insider sale (28.5k ADS) worth ~US$440k; immaterial versus Takeda’s float—neutral signal.
The filing is a routine Form 144 notification. The proposed disposition amounts to ~0.02 % of Takeda’s outstanding ADSs and is valued at less than half a million dollars, negligible against the company’s multi-billion-dollar market capitalization. Because the shares stem from recently vested RSUs, the transaction likely serves liquidity or tax-planning purposes rather than signaling a view on fundamentals. No pattern of recent sales is noted, and the filer certifies absence of undisclosed negative information. Overall, I view the filing as not impactful for valuation or sentiment.
FAQ
How many Takeda (TAK) ADSs are being sold under this Form 144 notice?
What is the aggregate market value of the proposed Takeda ADS sale?
When is the approximate sale date listed in the Form 144 for Takeda?
What percentage of Takeda’s outstanding ADSs does the proposed sale represent?
Where will the Takeda ADSs be sold according to the filing?